



Universiteit
Leiden
The Netherlands

Biomarker discovery in diabetes mellitus and lipid metabolism: multi-platform glyco(proteo)mic approaches

Demus, D.A.

Citation

Demus, D. A. (2024, October 1). *Biomarker discovery in diabetes mellitus and lipid metabolism: multi-platform glyco(proteo)mic approaches*. Retrieved from <https://hdl.handle.net/1887/4093481>

Version: Publisher's Version


License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4093481>

Note: To cite this publication please use the final published version (if applicable).

CHAPTER

6



6. Apolipoprotein-CIII O-glycosylation is associated with micro- and macrovascular complications of type 2 diabetes

Annemieke Naber¹, Daniel Demus², Roderick Slieker^{3,4}, Simone Nicolardi², Joline W.J. Beulens^{4,5,6}, Petra J.M. Elders⁷, Aloysius G. Lieveise⁸, Eric J.G. Sijbrands¹, Leen M. 't Hart^{3,4,5,9}, Manfred Wuhrer², Mandy van Hoek¹

¹ Department of Internal Medicine, Erasmus MC University Medical Center Rotterdam, Netherlands

² Center for Proteomics and Metabolomics, Leiden University Medical Center, the Netherlands

³ Department of Cell and Chemical Biology, Leiden University Medical Center, the Netherlands

⁴ Department of Epidemiology and Data Science, Amsterdam UMC, location Vrije Universiteit Amsterdam, the Netherlands

⁵ Amsterdam Public Health, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands

⁶ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

⁷ Department of General Practice, Amsterdam Public Health Institute, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands

⁸ Department of Internal Medicine, Maxima Medical Center, Eindhoven, the Netherlands

⁹ Department of Biomedical Data Science, section Molecular Epidemiology, Leiden University Medical Center, the Netherlands

Reprinted and adapted: Naber, A.; Demus, D.; Slieker, R.C.; Nicolardi, S.; Beulens, J.W.J.; Elders, P.J.M.; Lieveise, A.G.; Sijbrands, E.J.G.; 't Hart, L.M.; Wuhrer, M.; et al. Apolipoprotein-CIII O-Glycosylation Is Associated with Micro- and Macrovascular Complications of Type 2 Diabetes. *Int. J. Mol. Sci.* 2024, 25, 5365. <https://doi.org/10.3390/ijms25105365>

Copyright © 2024 The Authors

ABSTRACT

Apolipoprotein-CIII (apo-CIII) inhibits the clearance of triglycerides from circulation and is associated with an increased risk of diabetes complications. It exists in four main proteoforms: O-glycosylated variants containing either zero, one, or two sialic acids and a non-glycosylated variant. O-glycosylation may affect the metabolic functions of apo-CIII. We investigated the associations of apo-CIII glycosylation in blood plasma, measured by mass spectrometry of the intact protein, and genetic variants with micro- and macrovascular complications (retinopathy, nephropathy, neuropathy, cardiovascular disease) of type 2 diabetes in a DiaGene study (n = 1571) and the Hoorn DCS cohort (n = 5409). Mono-sialylated apolipoprotein-CIII (apo-CIII₁) was associated with a reduced risk of retinopathy ($\beta = -7.215$, 95% CI -11.137 to -3.294) whereas disialylated apolipoprotein-CIII (apo-CIII₂) was associated with an increased risk ($\beta = 5.309$, 95% CI 2.279 to 8.339). A variant of the *GALNT2*-gene (rs4846913), previously linked to lower apo-CIII_{0a}, was associated with a decreased prevalence of retinopathy (OR = 0.739, 95% CI 0.575 to 0.951). Higher apo-CIII₁ levels were associated with neuropathy ($\beta = 7.706$, 95% CI 2.317 to 13.095) and lower apo-CIII_{0a} with macrovascular complications ($\beta = -9.195$, 95% CI -15.847 to -2.543). In conclusion, apo-CIII glycosylation was associated with the prevalence of micro- and macrovascular complications of diabetes. Moreover, a variant in the *GALNT2*-gene was associated with apo-CIII glycosylation and retinopathy, suggesting a causal effect. The findings facilitate a molecular understanding of the pathophysiology of diabetes complications and warrant consideration of apo-CIII glycosylation as a potential target in the prevention of diabetes complications.

INTRODUCTION

Type 2 diabetes and its micro- and macrovascular complications pose worldwide problems in terms of morbidity, mortality, healthcare costs and low quality of life²⁰⁴. Despite treatment efforts, a substantial residual risk of these complications remains^{205, 206}. Diabetic dyslipidaemia is one of the main risk factors for complications in type 2 diabetes and is characterised by a severely atherogenic lipid profile^{207, 208}. Apolipoprotein-CIII (apo-CIII) levels have been linked to dyslipidaemia²⁰⁹.

Apo-CIII is a protein involved in the metabolism of triglyceride-rich lipoproteins (TRLs)¹²³. It has detrimental effects on the vascular wall by reducing the clearance of TRLs via lipoprotein lipase (LPL)-dependent and -independent pathways¹⁶⁰. Apo-CIII enhances monocyte adhesion to the endothelium²¹⁰ and the binding of apoB-containing lipoproteins to vascular proteoglycans¹²². High levels of apo-CIII are found in individuals with diabetes mellitus^{211, 212} and are related to reduced insulin sensitivity⁵⁸ and apoptosis of pancreatic beta-cells¹⁷². Apo-CIII levels have also been associated with diabetic retinopathy and nephropathy²¹³⁻²¹⁵, and with increased cardiovascular disease risk in the general population and type 2 diabetes¹²⁷. Genetic studies support the causality of this relationship with ischemic cardiovascular disease¹⁷⁰. Consequently, it has been suggested that apo-CIII levels could be reduced by anti-apo-CIII antibody, antisense RNA, and silencing RNA therapies, to reduce vascular disease risk^{130, 216, 217}.

Posttranslational modifications, such as enzymatic glycosylation, can alter the function of apolipoproteins^{59, 135, 136}. Apo-CIII exists in four main proteoforms: the native, non-glycosylated proteoform, and *O*-glycosylated proteoforms with either zero, one or two sialic acids^{35, 58}. It has been recognised that glycosylation influences apo-CIII function and its relationship with lipid metabolism and cardiovascular disease^{58, 59, 150}. Non- and monosialylated apo-CIII are associated with the formation of small-dense low-density lipoproteins (LDL)²¹⁸. Altered apo-CIII glycosylation affects the inhibition of LPL by apo-CIII¹³⁵ and the interaction of LDL with the vascular wall¹³⁶. Moreover, Apo-CIII

glycoforms are differentially cleared by hepatic receptors⁵⁹. Different glycosylation patterns of apo-CIII have been observed in liver disease, metabolic syndrome, and the associated factors body weight and insulin sensitivity^{10, 12}. Aberrant apo-CIII glycosylation patterns might increase the risk of complications in type 2 diabetes. These glycosylation patterns may have implications for the efficacy of preventive therapies addressing diabetes complications and in particular for lipid lowering agents in type 2 diabetes.

In the present study, we investigated the relation of apo-CIII glycosylation with the prevalence and incidence of diabetic retinopathy, nephropathy, neuropathy, and macrovascular complications. The direction of these relationships was assessed with recently identified genetic variants associated with apo-CIII glycosylation. We used data from the DiaGene cohort, a prospective study of type 2 diabetes conducted in Eindhoven, the Netherlands¹⁴¹. Genetic associations were replicated and meta-analysed in an independent cohort with type 2 diabetes patients in West-Friesland, the Netherlands: the Hoorn Diabetes Care System (Hoorn DCS)¹⁸⁰.

RESEARCH DESIGN AND METHODS

Study design

Plasma samples from the DiaGene study were used. In short, the DiaGene study is an all case-control study addressing all lines of healthcare with prospective follow-up in the cities of Eindhoven and Veldhoven, the Netherlands. The DiaGene study sought to include all type 2 diabetes patients in hospital and primary care at a given time point in the past. A prospective follow-up was performed from that moment onwards. Inclusion took place between 2006 and 2011, with a median follow-up duration of 7.8 years. This study has been described in detail elsewhere¹⁴¹. The current study was restricted to cases with type 2 diabetes for which apo-CIII glycosylation measurements were available (n=1,571).

Data from the Hoorn DCS (n=5,409) were used for replication of genetic associations with complications of type 2 diabetes. This cohort has been described in detail elsewhere¹⁸⁰. In short, biobanking materials and data on annual examinations for micro- and macrovascular complications have been collected from primary care type 2 diabetes patients, with prospective follow-up. The Hoorn DCS study included newly diagnosed type 2 diabetes patients. Afterwards, follow-up was performed. Inclusion took place between 1998 and 2014 in the region of West Friesland in the Netherlands. The median follow-up duration was 9.0 years.

All participants gave their written informed consent. Both studies were approved by the Medical Ethics Committees of the involved hospitals in compliance with the Declaration of Helsinki principles (DiaGene MEC-2004-230, Hoorn DCS 2007/57).

Definitions

Type 2 diabetes was defined in accordance with the American Diabetes Association and the WHO guidelines^{219, 220} for both the DiaGene and the Hoorn DCS cohorts^{141, 180}.

People with other types of diabetes were excluded from both cohorts.

Retinopathy, nephropathy, and neuropathy were considered microvascular complications. Diabetic retinopathy was diagnosed using fundus photography. Diabetic

nephropathy was defined as albumin/creatinine ratio (ACR) ≥ 2.5 for men or ≥ 3.5 for women present at two of three consecutive measurements, or when ACR ≥ 12.5 for men or ≥ 17.5 for women was present at one measurement. Diabetic neuropathy was defined by a podiatrist, neurologist or the patient's treating physician. Only hospital treated participants of the DiaGene study had information about diabetic neuropathy (n=611). Macrovascular complications in the DiaGene study comprised ischemic heart disease (myocardial infarction, percutaneous coronary intervention or coronary artery bypass graft), cerebrovascular accident, transient ischemic attack and peripheral arterial disease. In the DiaGene, information on cardiovascular disease for hospital-treated patients was retrieved from the medical records, and for primary care-treated patients from self-reporting¹⁴¹. In the Hoorn DCS, cardiovascular events were reported during the annual visits and verified against the medical records from the regional hospital and general practitioners. More detailed information on the definitions and data collection of micro- and macrovascular complications of diabetes has been described previously¹⁸⁰.

Apo-CIII glycosylation analysis

Ultrahigh-resolution matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry (MALDI FT-ICR MS) method, described elsewhere¹⁷⁹, was applied to assess the relative levels of apo-CIII proteoforms in blood plasma samples of the DiaGene cohort. Apo-CIII exists in four main proteoforms: glycosylated variants containing a mucin-type core-1 O-glycan with either zero, one or two sialic acids (apo-CIII_{0c}, apo-CIII₁ and apo-CIII₂ respectively) and a non-glycosylated variant (apo-CIII_{0a}) (**Figure 1**)^{35, 58}. The sum of apo-CIII_{0c}, apo-CIII₁, and apo-CIII₂ was set to 1.0 to obtain the proportion of these three glycoforms within all glycosylated species of apo-CIII. These normalised relative peak intensities of the glycosylated variants apo-CIII_{0c}, apo-CIII₁, and apo-CIII₂ were used to assess associations with apo-CIII sialylation status. The relative peak intensity of apo-CIII_{0a}, normalised to the sum of all four proteoforms (apo-CIII_{0a}, apo-CIII_{0c}, apo-CIII₁, and apo-CIII₂), was used to assess associations with apo-CIII glycosylation status. We used beta to present the outcome

measures of our regression models on glycosylation traits to ease the interpretation. Quality control of mass spectrometry (MS) data was performed as described elsewhere¹⁷⁹. Samples not meeting the acceptable quality parameters were excluded from the subsequent analysis. Apo-CIII glycosylation data was only available in the DiaGene study.




Figure 1. Apo-CIII glycoforms. Apo-CIII has four main proteoforms: apo-CIII_{0a} is the non-glycosylated form; apo-CIII_{0c} is glycosylated, without sialic acid; and apo-CIII₁ and apo-CIII₂ are glycosylated with one or two sialic acids respectively. Black symbol = apo-CIII protein; yellow square = N-acetylgalactosamine; yellow circle = galactose; purple diamond = N-acetylneuraminic acid (sialic acid).

Experimental design and statistical analysis

A total of 1571 DiaGene samples passed apo-CIII glycosylation data quality control and contained sufficient clinical information for the analysis. Missing data on covariates (duration of diabetes, HbA1c, use of lipid-lowering medication, and use of insulin) within the DiaGene study were imputed using multiple imputations by predictive mean matching in SPSS. The maximum count of imputations per variable was 105 in DiaGene; all imputed variables had <7% missing values. Covariates within the DCS Hoorn had <2% missing values per covariate, and therefore were not imputed (**Supplementary Table S1**).

Table S1. Number of missings per variable.

| Variable | DiaGene | | DCS Hoorn | |
|---------------------------|---------|------------|-----------|------------|
| | Number | Percentage | Number | Percentage |
| Sex | 0 | 0.00 | 0 | 0.00 |
| Age | 0 | 0.00 | 0 | 0.00 |
| Duration of diabetes | 105 | 6.7 | 37 | 0.68 |
| BMI | 107 | 6.8 | 39 | 0.72 |
| HbA1c | 78 | 5.0 | 107 | 1.98 |
| Systolic blood pressure | 105 | 6.7 | 76 | 1.41 |
| Diastolic blood pressure | 104 | 6.6 | 76 | 1.41 |
| Mean arterial pressure | 105 | 6.7 | 76 | 1.41 |
| Creatinine | 102 | 6.5 | 113 | 2.09 |
| HDL-cholesterol | 80 | 5.1 | 103 | 1.90 |
| non-HDL-cholesterol | 80 | 5.1 | 104 | 1.92 |
| LDL-cholesterol | 102 | 6.5 | 194 | 3.59 |
| Total cholesterol | 77 | 4.9 | 98 | 1.81 |
| Triglycerides | 79 | 5.0 | 100 | 1.85 |
| Lipid lowering medication | 97 | 6.2 | 0 | 0.00 |
| Insulin or analogues | 97 | 6.2 | 0 | 0.00 |
| Smoking | 149 | 9.5 | 183 | 3.38 |

Associations of apo-CIII glycosylation with micro- and macrovascular complications at baseline and follow-up were investigated using logistic regression and Cox proportional hazards models, respectively. Prospective analyses were performed after excluding prevalent complications. Analyses were performed for retinopathy, nephropathy, neuropathy, and macrovascular complications separately.

Two models were applied for all analyses. Model 1 was adjusted for age and sex. Model 2 was adjusted for age, sex, haemoglobin A1c (HbA1c), and duration of diabetes. The outcomes of Model 1 reflect the broad differences between diabetes patients with and without one of the complications. In contrast, Model 2 reflects the differences not mediated through the duration of type 2 diabetes or its regulation, with HbA1c as a proxy.

We performed two-sided *t*-tests to analyse the associations of insulin use and lipid-lowering therapy with apo-CIII glycosylation. Subsequently, we performed two sensitivity analyses: adding insulin use to Model 1, and the use of lipid-lowering therapy (fibrates and statins) to Model 2.

In our previous genome-wide association study (GWAS) of the apo-CIII glycosylation²²¹, we identified genetic variants associated with apo-CIII O-glycosylation. We selected two loci from this GWAS, with previous links to triglyceride levels. We analysed the associations of these genetic variants with micro- and macrovascular complications, applying the same models as described above. These analyses were replicated in the Hoorn DCS cohort and meta-analysed using a random effects model for the two cohorts using the package 'meta' version 7.0-0²²². Heterogeneity between cohorts was also evaluated using I^2 values (**Supplementary Table S2**)²²³.

Statistical analyses within the DiaGene study were performed using SPSS version 25. Analyses of the Hoorn Diabetes Care System (DCS) cohort and the meta-analysis were performed using R version 4.0.5. For the analysis with apo-CIII glycosylation, the Bonferroni corrected *p*-value for significance was calculated as 0.013 (0.05/4) based on the four main apo-CIII proteoforms. For the analyses of the four genetic variants and complications of diabetes, we used a Bonferroni corrected *p*-value for a significance of 0.013 (0.05/4). Significance is given after Bonferroni correction unless stated otherwise.

Table S2. Measures of heterogeneity.

| <u>Retinopathy</u> | | Prevalence | | Incidence | |
|---------------------------|------------------------|------------|---------|-----------|---------|
| uniqlD | rsID (dbSNP build 146) | Model 1 | Model 2 | Model 1 | Model 2 |
| | | I2 | I2 | I2 | I2 |
| 1:230294715:A:C | rs4846913 | 0 | 0.459 | 0 | 0.511 |
| 1:230286016:C:T | rs35498929 | 0 | 0 | 0.756 | 0.652 |
| 1:230416320:C:T | rs3213497 | 0.104 | 0.496 | 0 | 0 |
| 2:27686480:A:G | rs67086575 | 0 | 0 | 0 | 0.116 |

| <u>Nephropathy</u> | | Prevalence | | Incidence | |
|---------------------------|------------------------|------------|---------|-----------|---------|
| uniqlD | rsID (dbSNP build 146) | Model 1 | Model 2 | Model 1 | Model 2 |
| | | I2 | I2 | I2 | I2 |
| 1:230294715:A:C | rs4846913 | 0 | 0 | 0.270 | 0.044 |
| 1:230286016:C:T | rs35498929 | 0 | 0 | 0 | 0 |
| 1:230416320:C:T | rs3213497 | 0 | 0 | 0 | 0 |
| 2:27686480:A:G | rs67086575 | 0.605 | 0.495 | 0 | 0 |

| <u>Macrovascular complications</u> | | Prevalence | | Indicence | |
|---|------------------------|------------|---------|-----------|---------|
| uniqlD | rsID (dbSNP build 146) | Model 1 | Model 2 | Model 1 | Model 2 |
| | | I2 | I2 | I2 | I2 |
| 1:230294715:A:C | rs4846913 | 0 | 0 | 0 | 0 |
| 1:230286016:C:T | rs35498929 | 0.390 | 0.415 | 0 | 0 |
| 1:230416320:C:T | rs3213497 | 0.132 | 0 | 0.568 | 0.681 |
| 2:27686480:A:G | rs67086575 | 0 | 0 | 0.640 | 0.406 |

RESULTS

Cohort characteristics

The characteristics of cases with type 2 diabetes of both cohorts are presented in Table 1; 45.8% and 44.6% were female, and the mean age was 65.1 (SD 10.6) and 61.1 (SD 11) years in the DiaGene and Hoorn DCS, respectively. Compared with the Hoorn DCS, individuals from the DiaGene study had a longer duration of type 2 diabetes (8.0 vs. 0.6 years). At inclusion, the prevalence of complications was higher in the DiaGene than in the Hoorn DCS for retinopathy (17.4 vs. 3.6%), nephropathy (22.1 vs. 9.2%), and macrovascular complications (40.4 vs. 2.1%). In the DiaGene study, 30.6% of the participants had neuropathy at inclusion, but the Hoorn DCS did not collect data on neuropathy. The incidence of complications during follow-up was comparable between the DiaGene and the Hoorn DCS (**Table 1**).

Table 1. General characteristics of the study populations

| | DiaGene (n=1,571) | Hoorn DCS (n=5,409) |
|--|------------------------------|--------------------------------|
| Female sex, n (%) | 719 (45.8) | 2,414 (44.6) |
| Age, year, mean (\pm SD) | 65.1 (10.6) | 61.1 (11) |
| Duration of diabetes, year, median (IQR) | 8.0 (10.6) | 0.6 (2.7) |
| BMI, kg/m ² , median (IQR) | 30.0 (6.3) | 29.4 (6.5) |
| HbA1c, %, median (IQR) | 6.8 (1.3) | 6.7 (1.4) |
| HbA1c, mmol/mol, median (IQR) | 50.8 (14.2) | 49.7 (15.8) |
| Systolic blood pressure, mmHg, mean (\pm SD) | 142.0 (19.0) | 142.5 (20) |
| Diastolic blood pressure, mmHg, mean (\pm SD) | 77.5 (9.9) | 80.8 (10) |
| Mean arterial pressure, mmHg, mean (\pm SD) | 99.0 (11.0) | 101.4 (12) |
| Creatinine, μ mol/l, median (IQR) | 77.0 (25.0) | 79.9 (21.7) |
| HDL-cholesterol, mmol/L, median (IQR) | 1.1 (0.4) | 1.2 (0.4) |
| Non-HDL-cholesterol, mmol/L, median (IQR) | 3.0 (1.1) | 3.8 (1.5) |
| LDL-cholesterol, mmol/L, mean (\pm SD) | 2.5 (0.8) | 2.9 (1.5) |
| Total Cholesterol, mmol/L, median (IQR) | 4.2 (1.1) | 5.0 (1.6) |
| Triglycerides, mmol/L, median (IQR) | 1.4 (1.0) | 1.7 (1.1) |
| <i>Medication use, n (%)</i> | | |
| Statins or fibrates | 1020 (69.2) | 2276 (42.1) |
| Insulin or analogues | 463 (31.4) | 447 (8.3) |
| <i>Smoking, n (%)</i> | | |
| Never | 361 (25.4) | 1,667 (31.9) |
| Former | 804 (56.5) | 2,429 (46.5) |
| Current | 257 (18.1) | 1,130 (21.6) |
| <i>Complications, n-case/n-total (%)</i> | | |
| Prevalent Retinopathy | 257/1,478 (17.4) | 194/5,321 (3.6) |
| Incident Retinopathy | 175/1,168 (15.0) | 824/5,127 (16.1) |
| Prevalent Nephropathy | 309/1,401 (22.1) | 499/5,407 (9.2) |
| Incident Nephropathy | 206/1,058 (19.5) | 1009/4,908 (20.6) |
| Prevalent Neuropathy | 187/611 (30.6) | NA |

| | | |
|---------------------------------|------------------|-----------------|
| Incident Neuropathy | 192/400 (48.0) | NA |
| Prevalent macrovascular disease | 536/1,328 (40.4) | 111/5,396 (2.1) |
| Incident macrovascular disease | 86/913 (9.4) | 438/5,285 (8.3) |

BMI: body mass index; HDL: high-density lipoprotein; LDL: low density lipoprotein. Continuous data are presented as mean (and standard deviation) or median (and interquartile range) for normal and non-normal distributions respectively. The distribution of the clinical variables was considered normal when Skewness and Kurtosis were within the range of -1 to +1.

Associations of apo-CIII glycosylation with micro- and macrovascular complications in the DiaGene Study

Apo-CIII₁ and apo-CIII₂ levels showed strong associations with the prevalence (**Table 2**) and incidence of retinopathy (**Table 3**). In Model 1, apo-CIII₁ was associated with a decreased prevalence of retinopathy ($\beta = -7.215$, 95% CI -11.137 to -3.294), while apo-CIII₂ was associated with an increased prevalence ($\beta = 5.309$, 95% CI 2.279 to 8.339). These associations lost significance in Model 2, and the effect size was slightly reduced but showed the same trend. The association of apo-CIII_{0a} with an increased prevalence of retinopathy reached suggestive significance in Model 2 ($\beta = 9.968$, 95% CI 1.437 to 18.499), after adjustment for duration of diabetes and HbA1c. Apo-CIII₂ was significantly associated with incident retinopathy in Model 1 ($\beta = 4.484$, 95% CI 1.158 to 7.810). The associations of apo-CIII₁ and apo-CIII₂ with prevalent and incident retinopathy had consistent directions of effect.

For nephropathy, apo-CIII₁ was associated with a decreased prevalence ($\beta = -3.945$, 95% CI 7.716 to -0.174), but did not reach Bonferroni-corrected significance ($p = 0.040$) (**Table 2**). Adding covariates in Model 2 did not alter the direction of the association. Also, the direction and magnitude of the effect for the association of apo-CIII₁ and incident nephropathy were similar to the association found at baseline (**Table 3**).

Apo-CIII₁ and apo-CIII₂ levels were associated with neuropathy (**Table 2**). Apo-CIII₁ was significantly associated with an increased prevalence of neuropathy ($\beta = 7.706$, 95% CI 2.317 to 13.095), while apo-CIII₂ was associated with a decreased prevalence of neuropathy without reaching Bonferroni-corrected significance ($\beta = -4.968$, 95% CI -9.065 to -0.871 , $p = 0.017$). The direction of effects and their significance were similar in Model 2. The analysis for incident neuropathy did not reach significance but showed a similar direction of effects (**Table 3**).

Apo-CIII_{0a} levels were associated with macrovascular complications of diabetes (**Table 2**). This glycoform had a significant negative association with the prevalence of macrovascular complications in Model 1 ($\beta = -9.195$, 95% CI -15.847 to -2.543), which remained significant in Model 2 and the sensitivity analysis for insulin use (**Table 2 and Supplementary Table S3**). This association lost significance in the analysis of the incidence of macrovascular complications (**Table 3**). Nevertheless, the effect size and trend were similar.

The use of lipid-reducing agents was associated with lower relative levels of apo-CIII_{0a} and insulin use was associated with lower apo-CIII₁ and higher apo-CIII₂ (**Supplementary Table S4**). Most associations persisted after sensitivity analysis for the use of lipid-lowering medication and insulin (**Supplementary Table S3**).

Table 2. Associations of apo-CIII proteoforms with prevalent complications of type 2 diabetes in the DiaGene study.

| Retinopathy | | | | | | |
|------------------------|---------|-------------------|---------------|---------|-------------------|--------------|
| Proteoform | Model 1 | | | Model 2 | | |
| | Beta | 95% CI | p-Value | Beta | 95% CI | p-Value |
| Apo-CIII _{0a} | 4.053 | -3.502 to 11.609 | 0.293 | 9.968 | 1.437 to 18.499 | 0.022 |
| Apo-CIII _{0c} | -3.930 | -9.252 to 1.392 | 0.148 | -3.372 | -9.213 to 2.468 | 0.258 |
| Apo-CIII ₁ | -7.215 | -11.137 to -3.294 | 0.0003 | -4.121 | -8.543 to 0.301 | 0.068 |
| Apo-CIII ₂ | 5.309 | 2.279 to 8.339 | 0.0006 | 3.379 | -0.024 to 6.783 | 0.052 |
| Nephropathy | | | | | | |
| Apo-CIII _{0a} | 0.486 | -6.938 to 7.910 | 0.898 | 2.403 | -5.132 to 9.938 | 0.532 |
| Apo-CIII _{0c} | 0.363 | -4.519 to 5.244 | 0.884 | 0.890 | -4.082 to 5.861 | 0.726 |
| Apo-CIII ₁ | -3.945 | -7.716 to -0.174 | 0.040 | -2.468 | -6.338 to 1.402 | 0.211 |
| Apo-CIII ₂ | 2.377 | -0.512 to 5.266 | 0.107 | 1.386 | -1.589 to 4.361 | 0.361 |
| Neuropathy | | | | | | |
| Apo-CIII _{0a} | 5.505 | -4.277 to 15.287 | 0.270 | 5.871 | -3.979 to 15.720 | 0.243 |
| Apo-CIII _{0c} | 1.064 | -5.392 to 7.520 | 0.747 | 0.951 | -5.545 to 7.447 | 0.774 |
| Apo-CIII ₁ | 7.706 | 2.317 to 13.095 | 0.005 | 8.000 | 2.558 to 13.441 | 0.004 |
| Apo-CIII ₂ | -4.968 | -9.065 to -0.871 | 0.017 | -5.116 | -9.260 to -0.972 | 0.016 |
| Macrovascular disease | | | | | | |
| Apo-CIII _{0a} | -9.195 | -15.847 to -2.543 | 0.007 | -8.795 | -15.471 to -2.118 | 0.010 |
| Apo-CIII _{0c} | 0.635 | -3.615 to 4.885 | 0.770 | 0.880 | -3.392 to 5.152 | 0.686 |
| Apo-CIII ₁ | -0.123 | -3.429 to 3.184 | 0.942 | 0.301 | -3.042 to 3.644 | 0.860 |
| Apo-CIII ₂ | -0.077 | -2.622 to 2.468 | 0.953 | -0.401 | -2.979 to 2.176 | 0.760 |

Model 1: adjusted for age and sex; Model 2: adjusted for age, sex, duration of diabetes, and HbA1c. Apo-CIII_{0a} normalised to all four proteoforms: apo-CIII_{0a}, apo-CIII_{0c}, apo-CIII₁, and apo-CIII₂. The sum of the glycoforms Apo-CIII_{0c}, Apo-CIII₁, and Apo-CIII₂ was set to 1.0. Beta represents the change of prevalence of the respective complication per increase of 1 standard deviation of the relative peak intensity of the proteoform of apo-CIII. Bold for $p < 0.05$, bold and underlined for $p < 0.013$.

Table 3. Associations of apo-CIII proteoforms with incident complications of type 2 diabetes in the DiaGene study.

| Retinopathy | | | | | | |
|------------------------|---------|------------------|--------------|---------|------------------|---------|
| Proteoform | Model 1 | | | Model 2 | | |
| | Beta | 95% CI | p-Value | Beta | 95% CI | p-Value |
| Apo-CIII _{0a} | -4.554 | -13.457 to 4.348 | 0.316 | 3.171 | -5.753 to 12.094 | 0.486 |
| Apo-CIII _{0c} | -5.834 | -11.866 to 0.198 | 0.058 | -4.784 | -10.840 to 1.271 | 0.122 |
| Apo-CIII ₁ | -4.958 | -9.268 to -0.649 | 0.024 | -2.037 | -6.521 to 2.447 | 0.373 |
| Apo-CIII ₂ | 4.484 | 1.158 to 7.810 | 0.008 | 2.522 | -0.962 to 6.006 | 0.156 |
| Nephropathy | | | | | | |
| Apo-CIII _{0a} | -5.189 | -13.555 to 3.178 | 0.224 | -4.794 | -13.196 to 3.608 | 0.263 |
| Apo-CIII _{0c} | -0.130 | -5.465 to 5.204 | 0.962 | -0.488 | -5.831 to 4.855 | 0.858 |
| Apo-CIII ₁ | -2.852 | -6.933 to 1.229 | 0.171 | -2.761 | -6.936 to 1.413 | 0.195 |
| Apo-CIII ₂ | 1.366 | -1.863 to 4.595 | 0.407 | 1.400 | -1.877 to 4.677 | 0.402 |
| Neuropathy | | | | | | |
| Apo-CIII _{0a} | -5.944 | -14.462 to 2.573 | 0.171 | -5.555 | -14.206 to 3.097 | 0.208 |
| Apo-CIII _{0c} | 3.525 | -1.469 to 8.519 | 0.166 | 2.213 | -2.896 to 7.323 | 0.396 |
| Apo-CIII ₁ | 0.647 | -3.527 to 4.821 | 0.761 | 0.398 | -3.896 to 4.691 | 0.856 |
| Apo-CIII ₂ | -1.981 | -5.206 to 1.245 | 0.229 | -1.308 | -4.601 to 1.984 | 0.436 |
| Macrovascular Disease | | | | | | |
| Apo-CIII _{0a} | -6.948 | -19.786 to 5.890 | 0.289 | -3.852 | -16.455 to 8.751 | 0.549 |
| Apo-CIII _{0c} | 0.564 | -7.660 to 8.788 | 0.893 | 0.992 | -6.978 to 8.962 | 0.807 |
| Apo-CIII ₁ | -2.327 | -8.512 to 3.857 | 0.461 | 0.244 | -6.016 to 6.504 | 0.939 |
| Apo-CIII ₂ | 0.639 | -4.317 to 5.595 | 0.800 | -1.096 | -6.055 to 3.864 | 0.665 |

Model 1: adjusted for age and sex; Model 2: adjusted for age, sex, duration of diabetes, and HbA1c. Apo-CIII_{0a} normalised to all four proteoforms: apo-CIII_{0a}, apo-CIII_{0c}, apo-CIII₁, and apo-CIII₂. The sum of the glycoforms Apo-CIII_{0c}, Apo-CIII₁, and Apo-CIII₂ was set to 1.0. Beta represents the change of incidence of the respective complication per increase of 1 standard deviation of the relative peak intensity of the proteoform of apo-CIII. Bold for $p < 0.05$, bold and underlined for $p < 0.013$.

Table S3. Association of apo-CIII proteoforms with prevalent and incident complications of type 2 diabetes, sensitivity analyses in the DiaGene cohort.

| <i>Prevalence</i> | | | | | | | | |
|------------------------|-------------------|--------|--------|--------------|-------------------|--------|--------|--------------|
| <u>Retinopathy</u> | Sens. Lipid Meds | | | | Sens. Insulin use | | | |
| | 95% C.I. for beta | | | | 95% C.I. for beta | | | |
| | Beta | lower | upper | p-value | Beta | lower | upper | p-value |
| Apo-CIII _{0a} | 8.935 | 0.314 | 17.556 | 0.042 | 4.115 | -3.784 | 12.013 | 0.307 |
| Apo-CIII _{0c} | -3.202 | -9.049 | 2.644 | 0.283 | -3.901 | -9.431 | 1.629 | 0.167 |
| Apo-CIII ₁ | -4.355 | -8.771 | 0.061 | 0.053 | -5.488 | -9.626 | -1.350 | 0.009 |
| Apo-CIII ₂ | 3.460 | 0.065 | 6.855 | 0.046 | 4.329 | 1.125 | 7.533 | 0.008 |

| <i>Prevalence</i> | | | | | | | | |
|------------------------|-------------------|--------|--------|---------|-------------------|--------|-------|---------|
| <u>Nephropathy</u> | Sens. Lipid Meds | | | | Sens. Insulin use | | | |
| | 95% C.I. for beta | | | | 95% C.I. for beta | | | |
| | Beta | lower | upper | p-value | Beta | lower | upper | p-value |
| Apo-CIII _{0a} | 2.504 | -5.094 | 10.103 | 0.518 | 0.332 | -7.121 | 7.784 | 0.931 |
| Apo-CIII _{0c} | 0.883 | -4.088 | 5.854 | 0.728 | 0.378 | -4.528 | 5.283 | 0.880 |
| Apo-CIII ₁ | -2.460 | -6.334 | 1.414 | 0.213 | -3.323 | -7.135 | 0.490 | 0.088 |
| Apo-CIII ₂ | 1.383 | -1.594 | 4.359 | 0.363 | 2.015 | -0.903 | 4.933 | 0.176 |

| <i>Prevalence</i> | | | | | | | | |
|------------------------|-------------------|--------|--------|--------------|-------------------|--------|--------|--------------|
| <u>Neuropathy</u> | Sens. Lipid Meds | | | | Sens. Insulin use | | | |
| | 95% C.I. for beta | | | | 95% C.I. for beta | | | |
| | Beta | lower | upper | p-value | Beta | lower | upper | p-value |
| Apo-CIII _{0a} | 5.602 | -4.342 | 15.545 | 0.270 | 5.255 | -4.579 | 15.089 | 0.295 |
| Apo-CIII _{0c} | 0.924 | -5.572 | 7.421 | 0.780 | 1.061 | -5.414 | 7.537 | 0.748 |
| Apo-CIII ₁ | 7.933 | 2.487 | 13.379 | 0.004 | 8.190 | 2.741 | 13.640 | 0.003 |
| Apo-CIII ₂ | -5.061 | -9.209 | -0.914 | 0.017 | -5.221 | -9.349 | -1.093 | 0.013 |

| <i>Prevalence</i> | | | | | | | | |
|-------------------------------|-------------------|---------|-------|---------|-------------------|---------|--------|--------------|
| <u>Cardiovascular disease</u> | Sens. Lipid Meds | | | | Sens. Insulin use | | | |
| | 95% C.I. for beta | | | | 95% C.I. for beta | | | |
| | Beta | lower | upper | p-value | Beta | lower | upper | p-value |
| Apo-CIII _{0a} | -6.565 | -13.368 | 0.239 | 0.059 | -9.216 | -15.874 | -2.558 | 0.007 |
| Apo-CIII _{0c} | 0.805 | -3.525 | 5.135 | 0.716 | 0.715 | -3.546 | 4.976 | 0.742 |
| Apo-CIII ₁ | 0.778 | -2.636 | 4.192 | 0.655 | 0.184 | -3.142 | 3.509 | 0.914 |
| Apo-CIII ₂ | -0.665 | -3.301 | 1.971 | 0.621 | -0.282 | -2.839 | 2.276 | 0.829 |

| Retinopathy | | | | | | | | |
|------------------------|-------------------|---------|--------|---------|-------------------|---------|-------|---------|
| Proteoform | <i>Incidence</i> | | | | Sens. Insulin use | | | |
| | Sens. Lipid Meds | | | | Sens. Insulin use | | | |
| | 95% C.I. for beta | | | | 95% C.I. for beta | | | |
| | Beta | lower | upper | p-value | Beta | lower | upper | p-value |
| Apo-CIII _{0a} | 3.219 | -5.728 | 12.165 | 0.481 | -3.151 | -11.876 | 5.574 | 0.479 |
| Apo-CIII _{0c} | -4.788 | -10.849 | 1.273 | 0.122 | -5.500 | -11.426 | 0.427 | 0.069 |
| Apo-CIII ₁ | -2.041 | -6.529 | 2.447 | 0.373 | -2.076 | -6.386 | 2.233 | 0.345 |
| Apo-CIII ₂ | 2.527 | -0.964 | 6.018 | 0.156 | 2.820 | -0.516 | 6.157 | 0.098 |

| Nephropathy | | | | | | | | |
|------------------------|-------------------|---------|-------|---------|-------------------|---------|-------|---------|
| Proteoform | <i>Incidence</i> | | | | Sens. Insulin use | | | |
| | Sens. Lipid Meds | | | | Sens. Insulin use | | | |
| | 95% C.I. for beta | | | | 95% C.I. for beta | | | |
| | Beta | lower | upper | p-value | Beta | lower | upper | p-value |
| Apo-CIII _{0a} | -3.998 | -12.547 | 4.550 | 0.359 | -5.179 | -13.549 | 3.191 | 0.225 |
| Apo-CIII _{0c} | -0.669 | -5.998 | 4.659 | 0.806 | -0.131 | -5.466 | 5.204 | 0.962 |
| Apo-CIII ₁ | -2.566 | -6.790 | 1.658 | 0.234 | -2.949 | -7.080 | 1.183 | 0.162 |
| Apo-CIII ₂ | 1.324 | -1.971 | 4.619 | 0.431 | 1.402 | -1.847 | 4.651 | 0.398 |

| Neuropathy | | | | | | | | |
|------------------------|-------------------|---------|-------|---------|-------------------|---------|-------|---------|
| Proteoform | <i>Incidence</i> | | | | Sens. Insulin use | | | |
| | Sens. Lipid Meds | | | | Sens. Insulin use | | | |
| | 95% C.I. for beta | | | | 95% C.I. for beta | | | |
| | Beta | lower | upper | p-value | Beta | lower | upper | p-value |
| Apo-CIII _{0a} | -5.910 | -14.638 | 2.819 | 0.185 | -6.023 | -14.551 | 2.506 | 0.166 |
| Apo-CIII _{0c} | 2.161 | -2.949 | 7.271 | 0.407 | 3.527 | -1.457 | 8.512 | 0.165 |
| Apo-CIII ₁ | 0.297 | -4.001 | 4.595 | 0.892 | 0.637 | -3.542 | 4.817 | 0.765 |
| Apo-CIII ₂ | -1.236 | -4.539 | 2.066 | 0.463 | -1.981 | -5.202 | 1.240 | 0.228 |

| Cardiovascular disease | | | | | | | | |
|-------------------------------|-------------------|---------|-------|---------|-------------------|---------|-------|---------|
| Proteoform | <i>Incidence</i> | | | | Sens. Insulin use | | | |
| | Sens. Lipid Meds | | | | Sens. Insulin use | | | |
| | 95% C.I. for beta | | | | 95% C.I. for beta | | | |
| | Beta | lower | upper | p-value | Beta | lower | upper | p-value |
| Apo-CIII _{0a} | -3.356 | -16.092 | 9.379 | 0.605 | -6.659 | -19.420 | 6.102 | 0.306 |
| Apo-CIII _{0c} | 0.903 | -7.034 | 8.840 | 0.824 | 0.912 | -7.350 | 9.174 | 0.829 |
| Apo-CIII ₁ | 0.335 | -5.964 | 6.633 | 0.917 | -1.252 | -7.459 | 4.956 | 0.693 |
| Apo-CIII ₂ | -1.122 | -6.094 | 3.849 | 0.658 | -0.155 | -5.172 | 4.862 | 0.952 |

Bold for p<0.05; bold and underlined for p<0.05/4=0.013

Table S4. Association of Lipid lowering medication and insulin use with apo-CIII proteoforms in the DiaGene cohort

| Proteoform | Lipid Meds | | | | p-value | Insulin use | | | | |
|------------------------|------------|-------|-----------|-------|----------------------|-------------|-------|-----------|-------|---------------------|
| | Users | | Non-users | | | Users | | Non-users | | p-value |
| | Mean | SD | Mean | SD | | Mean | SD | Mean | SD | |
| Apo-CIII _{0a} | 0.035 | 0.017 | 0.039 | 0.019 | <u>0.0003</u> | 0.036 | 0.018 | 0.036 | 0.017 | 0.552 |
| Apo-CIII _{0c} | 0.114 | 0.027 | 0.114 | 0.026 | 0.742 | 0.113 | 0.026 | 0.115 | 0.027 | 0.261 |
| Apo-CIII ₁ | 0.670 | 0.035 | 0.674 | 0.037 | 0.058 | 0.667 | 0.036 | 0.673 | 0.035 | <u>0.004</u> |
| Apo-CIII ₂ | 0.215 | 0.045 | 0.211 | 0.049 | 0.184 | 0.219 | 0.045 | 0.211 | 0.046 | <u>0.005</u> |

Bold for $p < 0.05$; bold and underlined for $p < 0.05/4 = 0.013$. Mean (and standard deviation). P-values are for use versus non-use of the mentioned medication.

Apo-CIII glycosylation-associated genetic variants and complications of diabetes in the DiaGene and Hoorn DCS studies, a meta-analysis

The genetic variant rs4846913-A located in the *GALNT2* gene, previously associated with decreased apo-CIII_{0a}²²¹, was found to be negatively associated with prevalent retinopathy in Model 2 in the DiaGene study (OR = 0.739, 95% CI 0.575 to 0.951). However, it did not reach the Bonferroni significance level (**Table 4, Table 5, Figure 1**). This association remained in the sensitivity analysis for the use of lipid-lowering medications (OR = 0.722, 95% CI 0.559 to 0.932) and lost its significance after the sensitivity analysis for insulin use (**Supplementary Table S5**). These associations had the same direction of effect in the Hoorn DCS cohort.




Figure 2. Summary of associations of genetic variants, apo-CIII proteoforms and complications of diabetes. a) Rs4846913-A is associated with lower apo-CIII_{0a} and lower prevalence of retinopathy. Rs3213497-T is associated with lower apo-CIII_{0a} and decreased incidence of retinopathy and prevalence of nephropathy. Apo-CIII_{0a} is associated with higher prevalence of retinopathy. b) The four proteoforms of apo-CIII are associated with micro- and macrovascular complications of diabetes. Blue: negative associations, red: positive associations.

Table 4. Associations of genetic variants with prevalent complications of type 2 diabetes, Model 1 (adjusted for age and sex).

| Retinopathy | | | | DiaGene | | | Hoorn DCS | | | Meta-Analysis | |
|----------------------------|------------|----|----|---------|----------------|---------|-----------|----------------|---------|---------------|--------------|
| Locus | rsID | EA | RA | OR | 95% CI | p-Value | OR | 95% CI | p-Value | OR | p-Value |
| <i>GALNT2</i> | rs4846913 | A | C | 0.869 | 0.696 to 1.086 | 0.218 | 0.935 | 0.763 to 1.147 | 0.521 | 0.905 | 0.192 |
| <i>GALNT2</i> | rs35498929 | T | C | 0.884 | 0.637 to 1.227 | 0.461 | 0.897 | 0.651 to 1.236 | 0.508 | 0.891 | 0.324 |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 0.991 | 0.716 to 1.372 | 0.958 | 0.774 | 0.559 to 1.071 | 0.122 | 0.875 | 0.283 |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.819 | 0.594 to 1.128 | 0.221 | 0.929 | 0.701 to 1.231 | 0.606 | 0.879 | 0.231 |
| Nephropathy | | | | DiaGene | | | Hoorn DCS | | | Meta-Analysis | |
| Locus | rsID | EA | RA | OR | 95% CI | p-Value | OR | 95% CI | p-Value | OR | p-Value |
| <i>GALNT2</i> | rs4846913 | A | C | 0.912 | 0.988 to 0.795 | 0.912 | 1.033 | 0.904 to 1.179 | 0.637 | 1.020 | 0.730 |
| <i>GALNT2</i> | rs35498929 | T | C | 0.999 | 0.733 to 1.360 | 0.993 | 0.903 | 0.734 to 1.110 | 0.333 | 0.932 | 0.417 |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 0.853 | 0.619 to 1.175 | 0.331 | 0.819 | 0.667 to 1.005 | 0.056 | 0.829 | 0.033 |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.282 | 0.848 to 0.628 | 0.282 | 1.123 | 0.945 to 1.335 | 0.189 | 1.003 | 0.980 |
| Neuropathy | | | | DiaGene | | | Hoorn DCS | | | Meta-Analysis | |
| Locus | rsID | EA | RA | OR | 95% CI | p-Value | OR | 95% CI | p-Value | OR | p-Value |
| <i>GALNT2</i> | rs4846913 | A | C | 1.270 | 0.948 to 1.700 | 0.109 | NA | NA | NA | NA | NA |
| <i>GALNT2</i> | rs35498929 | T | C | 1.350 | 0.895 to 2.034 | 0.152 | NA | NA | NA | NA | NA |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 1.161 | 0.765 to 1.761 | 0.483 | NA | NA | NA | NA | NA |

| IFT172/NRBP1 | | rs67086575 | G | A | 0.989 | 0.664 to 1.472 | 0.956 | NA | NA | NA | NA | NA |
|-----------------------------|------------|------------|----|-------|----------------|----------------|-----------|----------------|---------|---------------|---------|----|
| Macrovascular Complications | | | | | DiaGene | | Hoorn DCS | | | Meta-Analysis | | |
| Locus | rsID | EA | RA | OR | 95% CI | p-Value | OR | 95% CI | p-Value | OR | p-Value | |
| <i>GALNT2</i> | rs4846913 | A | C | 1.103 | 0.922 to 1.320 | 0.283 | 1.056 | 0.806 to 1.385 | 0.691 | 1.014 | 0.869 | |
| <i>GALNT2</i> | rs35498929 | T | C | 0.917 | 0.711 to 1.184 | 0.507 | 1.236 | 0.846 to 1.806 | 0.273 | 1.029 | 0.842 | |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 0.983 | 0.755 to 1.280 | 0.900 | 1.256 | 0.875 to 1.803 | 0.216 | 1.076 | 0.534 | |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.937 | 0.736 to 1.194 | 0.601 | 0.840 | 0.572 to 1.234 | 0.375 | 0.909 | 0.358 | |

Beta represents the change of prevalence of the respective complication per increase of the effect allele. Bold for $p < 0.05$. EA, effect allele; RA, reference allele; NA, not available.

Table 5. Associations of genetic variants with prevalent complications of type 2 diabetes, Model 2 (adjusted for age, sex, duration of diabetes, and HbA1c).

| Retinopathy | | | | DiaGene | | Hoorn DCS | | | Meta-Analysis | | |
|----------------------------|------------|----|----|---------|----------------|--------------|-------|----------------|---------------|-------|---------|
| Locus | rsID | EA | RA | OR | 95% CI | p-Value | OR | 95% CI | p-Value | OR | p-Value |
| <i>GALNT2</i> | rs4846913 | A | C | 0.739 | 0.575 to 0.951 | 0.019 | 0.928 | 0.754 to 1.142 | 0.480 | 0.838 | 0.118 |
| <i>GALNT2</i> | rs35498929 | T | C | 0.858 | 0.592 to 1.244 | 0.419 | 0.890 | 0.642 to 1.234 | 0.485 | 0.876 | 0.292 |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 1.099 | 0.771 to 1.567 | 0.602 | 0.776 | 0.557 to 1.081 | 0.133 | 0.918 | 0.625 |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.857 | 0.598 to 1.226 | 0.398 | 0.934 | 0.703 to 1.242 | 0.640 | 0.903 | 0.372 |

| Nephropathy | | | | DiaGene | | | Hoorn DCS | | | Meta-Analysis | |
|-----------------------------|------------|----|----|---------|----------------|---------|-----------|----------------|---------|---------------|--------------|
| Locus | rsID | EA | RA | OR | 95% CI | p-Value | OR | 95% CI | p-Value | OR | p-Value |
| <i>GALNT2</i> | rs4846913 | A | C | 0.949 | 0.760 to 1.184 | 0.641 | 1.032 | 0.902 to 1.180 | 0.651 | 1.008 | 0.889 |
| <i>GALNT2</i> | rs35498929 | T | C | 0.996 | 0.726 to 1.367 | 0.982 | 0.889 | 0.721 to 1.097 | 0.272 | 0.920 | 0.351 |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 0.883 | 0.639 to 1.220 | 0.450 | 0.776 | 0.628 to 0.958 | 0.056 | 0.806 | 0.017 |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.868 | 0.639 to 1.189 | 0.366 | 1.118 | 0.938 to 1.333 | 0.212 | 1.018 | 0.884 |
| Neuropathy | | | | DiaGene | | | Hoorn DCS | | | Meta-Analysis | |
| <i>GALNT2</i> | rs4846913 | A | C | 1.254 | 0.935 to 1.681 | 0.130 | NA | NA | NA | NA | NA |
| <i>GALNT2</i> | rs35498929 | T | C | 1.350 | 0.895 to 2.038 | 0.153 | NA | NA | NA | NA | NA |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 1.182 | 0.779 to 1.795 | 0.432 | NA | NA | NA | NA | NA |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.978 | 0.656 to 1.459 | 0.914 | NA | NA | NA | NA | NA |
| Macrovascular Complications | | | | DiaGene | | | Hoorn DCS | | | Meta-Analysis | |
| <i>GALNT2</i> | rs4846913 | A | C | 1.091 | 0.911 to 1.307 | 0.343 | 1.036 | 0.781 to 1.374 | 0.806 | 1.075 | 0.354 |
| <i>GALNT2</i> | rs35498929 | T | C | 0.915 | 0.708 to 1.182 | 0.495 | 1.255 | 0.844 to 1.866 | 0.262 | 1.031 | 0.840 |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 0.990 | 0.760 to 1.289 | 0.939 | 1.216 | 0.831 to 1.780 | 0.314 | 1.059 | 0.606 |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.947 | 0.743 to 1.208 | 0.663 | 0.867 | 0.586 to 1.284 | 0.476 | 0.924 | 0.455 |

Beta represents the change in prevalence of the respective complication per increase of the effect allele. Bold for $p < 0.05$. EA, effect allele; RA, reference allele; NA, not available.

Table S5. Associations of lead SNPs with prevalent complications of type 2 diabetes, sensitivity analyses.

| Retinopathy | | Sens. Lipid Meds | | | | | | | | | | Sens. Insulin use | | | | | | | | | | |
|-----------------|---|------------------------|-------|-------|-------|---------|-----------------|-------|-------|---------|-----------------|-------------------|-------|---------|-----------------|-------|-----------|---------|-----------------|-------|-------|---------|
| | | DiaGene | | | | | Hoorn DCS | | | | | DiaGene | | | | | Hoorn DCS | | | | | |
| | | rsID (dbSNP build 146) | EA | RA | OR | p-value | 95% C.I. for OR | lower | upper | p-value | 95% C.I. for OR | lower | upper | p-value | 95% C.I. for OR | lower | upper | p-value | 95% C.I. for OR | lower | upper | p-value |
| 1:230294715-A:C | A | C | 0.722 | 0.559 | 0.932 | 0.012 | 0.927 | 0.753 | 1.142 | 0.475 | 0.865 | 0.685 | 1.092 | 0.223 | 0.937 | 0.763 | 1.150 | 0.532 | 0.937 | 0.763 | 1.150 | 0.532 |
| 1:230286016-C:T | T | C | 0.838 | 0.576 | 1.219 | 0.356 | 0.886 | 0.639 | 1.229 | 0.468 | 0.859 | 0.607 | 1.216 | 0.393 | 0.909 | 0.658 | 1.256 | 0.563 | 0.909 | 0.658 | 1.256 | 0.563 |
| 1:230416320-C:T | T | C | 1.118 | 0.782 | 1.599 | 0.540 | 0.781 | 0.561 | 1.088 | 0.144 | 1.077 | 0.765 | 1.517 | 0.670 | 0.765 | 0.552 | 1.061 | 0.109 | 0.765 | 0.552 | 1.061 | 0.109 |
| 2:27686480-A:G | G | A | 0.845 | 0.590 | 1.211 | 0.360 | 0.946 | 0.711 | 1.258 | 0.703 | 0.851 | 0.607 | 1.193 | 0.350 | 0.933 | 0.703 | 1.240 | 0.634 | 0.933 | 0.703 | 1.240 | 0.634 |

| Nephropathy | | Sens. Lipid Meds | | | | | | | | | | Sens. Insulin use | | | | | | | | | | |
|-----------------|---|------------------------|-------|-------|-------|---------|-----------------|-------|-------|---------|-----------------|-------------------|-------|---------|-----------------|-------|-----------|---------|-----------------|-------|-------|---------|
| | | DiaGene | | | | | Hoorn DCS | | | | | DiaGene | | | | | Hoorn DCS | | | | | |
| | | rsID (dbSNP build 146) | EA | RA | OR | p-value | 95% C.I. for OR | lower | upper | p-value | 95% C.I. for OR | lower | upper | p-value | 95% C.I. for OR | lower | upper | p-value | 95% C.I. for OR | lower | upper | p-value |
| 1:230294715-A:C | A | C | 0.947 | 0.759 | 1.183 | 0.633 | 1.032 | 0.902 | 1.181 | 0.645 | 0.988 | 0.794 | 1.230 | 0.916 | 1.034 | 0.905 | 1.181 | 0.626 | 1.034 | 0.905 | 1.181 | 0.626 |
| 1:230286016-C:T | T | C | 0.995 | 0.725 | 1.365 | 0.974 | 0.889 | 0.721 | 1.097 | 0.274 | 0.991 | 0.726 | 1.353 | 0.956 | 0.907 | 0.737 | 1.115 | 0.355 | 0.907 | 0.737 | 1.115 | 0.355 |
| 1:230416320-C:T | T | C | 0.884 | 0.639 | 1.222 | 0.455 | 0.774 | 0.626 | 0.956 | 0.017 | 0.874 | 0.633 | 1.207 | 0.413 | 0.817 | 0.666 | 1.003 | 0.054 | 0.817 | 0.666 | 1.003 | 0.054 |
| 2:27686480-A:G | G | A | 0.867 | 0.638 | 1.179 | 0.363 | 1.114 | 0.935 | 1.328 | 0.229 | 0.861 | 0.636 | 1.165 | 0.331 | 1.127 | 0.947 | 1.340 | 0.177 | 1.127 | 0.947 | 1.340 | 0.177 |

Neuropathy

Sens. Lipid Meds

Sens. Insulin use

| uniqID | rsID (dbSNP build 146) | DiaGene | | | | Hoorn DCS | | | | DiaGene | | | | Hoorn DCS | | | | | |
|-----------------|------------------------|-----------------|----|-------|---------|-----------------|-------|-------|---------|-----------------|-------|-------|---------|-----------------|-------|-------|---------|----|----|
| | | EA | RA | OR | p-value | OR | lower | upper | p-value | OR | lower | upper | p-value | OR | lower | upper | p-value | | |
| | | 95% C.I. for OR | | | | 95% C.I. for OR | | | | 95% C.I. for OR | | | | 95% C.I. for OR | | | | | |
| 1:230294715:A:C | r54846913 | A | C | 1.257 | 0.936 | 1.687 | 0.128 | NA | NA | NA | NA | 1.253 | 0.935 | 1.681 | 0.132 | NA | NA | NA | NA |
| 1:230286016:C:T | r535498929 | T | C | 1.353 | 0.895 | 2.043 | 0.151 | NA | NA | NA | NA | 1.316 | 0.870 | 1.992 | 0.194 | NA | NA | NA | NA |
| 1:230416320:C:T | r53213497 | T | C | 1.182 | 0.779 | 1.796 | 0.432 | NA | NA | NA | NA | 1.181 | 0.775 | 1.799 | 0.439 | NA | NA | NA | NA |
| 2:27686480:A:G | r567086575 | G | A | 0.978 | 0.656 | 1.460 | 0.914 | NA | NA | NA | NA | 1.022 | 0.683 | 1.528 | 0.917 | NA | NA | NA | NA |

Macrovascular complications

Sens. Lipid Meds

Sens. Insulin use

| uniqID | rsID (dbSNP build 146) | DiaGene | | | | Hoorn DCS | | | | DiaGene | | | | Hoorn DCS | | | | | |
|-----------------|------------------------|-----------------|----|-------|---------|-----------------|-------|-------|---------|-----------------|-------|-------|---------|-----------------|-------|-------|---------|-------|-------|
| | | EA | RA | OR | p-value | OR | lower | upper | p-value | OR | lower | upper | p-value | OR | lower | upper | p-value | | |
| | | 95% C.I. for OR | | | | 95% C.I. for OR | | | | 95% C.I. for OR | | | | 95% C.I. for OR | | | | | |
| 1:230294715:A:C | r54846913 | A | C | 1.120 | 0.932 | 1.345 | 0.226 | 1.045 | 0.786 | 1.389 | 0.761 | 1.102 | 0.920 | 1.319 | 0.292 | 1.061 | 0.806 | 1.396 | 0.672 |
| 1:230286016:C:T | r535498929 | T | C | 0.952 | 0.734 | 1.234 | 0.710 | 1.263 | 0.844 | 1.889 | 0.256 | 0.911 | 0.705 | 1.178 | 0.476 | 1.289 | 0.872 | 1.904 | 0.202 |
| 1:230416320:C:T | r53213497 | T | C | 0.951 | 0.727 | 1.243 | 0.711 | 1.194 | 0.810 | 1.761 | 0.371 | 0.994 | 0.763 | 1.295 | 0.962 | 1.231 | 0.852 | 1.780 | 0.268 |
| 2:27686480:A:G | r567086575 | G | A | 0.986 | 0.770 | 1.262 | 0.911 | 0.828 | 0.556 | 1.231 | 0.351 | 0.945 | 0.741 | 1.205 | 0.648 | 0.860 | 0.580 | 1.274 | 0.452 |

Bold for p<0.05, bold and underlined for p<0.05/4=0.013; EA, effect allele; RA, reference allele

The variant rs3213497-T located at an exonic non-coding RNA region in the GALNT2:RP5-956O18.3 gene, previously associated with apo-CIII_{oa}²²¹, was associated at a nominal significance level with a decreased incidence of retinopathy in our meta-analysis of the DiaGene and Hoorn DCS in Models 1 and 2 (HR = 0.830, $p = 0.009$ and HR = 0.834, $p = 0.012$ resp.) (**Table 6 and Table 7**). This association remained after the sensitivity analysis for lipid-lowering medication and insulin use, although without Bonferroni significance level (**Supplementary Table S6**). The same variant rs3213497-T was nominally significantly associated with decreased prevalence of nephropathy in the meta-analysis with OR = 0.806, $p = 0.017$ (**Table 5**).

Table 6. Associations of genetic variants with incident complications of type 2 diabetes, Model 1 (adjusted for age and sex).

| Retinopathy | | | | DiaGene | | | Hoorn DCS | | | Meta-Analysis | |
|-----------------------------|------------|----|----|---------|----------------|---------|-----------|----------------|--------------|---------------|--------------|
| Locus | rsID | EA | RA | HR | 95% CI | P-Value | HR | 95% CI | P-Value | HR | P-Value |
| <i>GALNT2</i> | rs4846913 | A | C | 0.992 | 0.778 to 1.266 | 0.949 | 1.100 | 0.997 to 1.214 | 0.057 | 1.084 | 0.082 |
| <i>GALNT2</i> | rs35498929 | T | C | 0.724 | 0.494 to 1.063 | 0.099 | 1.106 | 0.960 to 1.275 | 0.162 | 0.931 | 0.732 |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 0.696 | 0.468 to 1.037 | 0.075 | 0.851 | 0.734 to 0.988 | 0.034 | 0.830 | 0.009 |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.916 | 0.654 to 1.281 | 0.607 | 1.026 | 0.902 to 1.168 | 0.693 | 1.011 | 0.855 |
| Nephropathy | | | | DiaGene | | | Hoorn DCS | | | Meta-Analysis | |
| <i>GALNT2</i> | rs4846913 | A | C | 0.862 | 0.696 to 1.067 | 0.173 | 0.989 | 0.906 to 1.081 | 0.814 | 0.957 | 0.453 |
| <i>GALNT2</i> | rs35498929 | T | C | 1.049 | 0.774 to 1.423 | 0.756 | 0.952 | 0.831 to 1.091 | 0.480 | 0.968 | 0.601 |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 1.069 | 0.796 to 1.436 | 0.657 | 0.931 | 0.817 to 1.061 | 0.284 | 0.952 | 0.422 |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.961 | 0.719 to 1.286 | 0.791 | 0.987 | 0.876 to 1.112 | 0.828 | 0.983 | 0.767 |
| Neuropathy | | | | DiaGene | | | Hoorn DCS | | | Meta-Analysis | |
| <i>GALNT2</i> | rs4846913 | A | C | 1.040 | 0.827 to 1.308 | 0.735 | NA | NA | NA | NA | NA |
| <i>GALNT2</i> | rs35498929 | T | C | 1.258 | 0.897 to 1.766 | 0.184 | NA | NA | NA | NA | NA |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 0.974 | 0.683 to 1.388 | 0.883 | NA | NA | NA | NA | NA |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.857 | 0.617 to 1.191 | 0.358 | NA | NA | NA | NA | NA |
| Macrovascular Complications | | | | DiaGene | | | Hoorn DCS | | | Meta-Analysis | |

| | | | | | | | | | | | |
|----------------------------|------------|---|---|-------|----------------------|-------|-------|----------------------|-------|-------|-------|
| <i>GALNT2</i> | rs4846913 | A | C | 1.020 | 0.731 to 1.424 | 0.906 | 1.020 | 0.892 to 1.166 | 0.773 | 1.020 | 0.751 |
| <i>GALNT2</i> | rs35498929 | T | C | 0.954 | 0.589 to 1.548 | 0.850 | 1.128 | 0.930 to 1.370 | 0.222 | 1.103 | 0.287 |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 1.313 | 0.823 to 2.096 | 0.253 | 0.885 | 0.722 to 1.086 | 0.242 | 1.018 | 0.926 |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.608 | 0.355 to 1.040 | 0.069 | 0.985 | 0.822 to 1.180 | 0.867 | 0.830 | 0.418 |

Beta represents the change of incidence of the respective complication per increase of the effect allele. Bold for $p < 0.05$, bold and underlined for $p < 0.013$. EA, effect allele; RA, reference allele; NA, not available.

Table 7. Associations of genetic variants with incident complications of type 2 diabetes, Model 2 (adjusted for age, sex, duration of diabetes, and HbA1c).

| Retinopathy | | | | DiaGene | | | Hoorn DCS | | | Meta-Analysis | |
|----------------------------|------------|----|----|---------|----------------------|-----------------|-----------|----------------------|-----------------|---------------|-----------------|
| Locus | rsID | EA | RA | HR | 95% CI | <i>P</i> -Value | HR | 95% CI | <i>P</i> -Value | HR | <i>P</i> -Value |
| <i>GALNT2</i> | rs4846913 | A | C | 0.884 | 0.684 to 1.142 | 0.344 | 1.081 | 0.978 to 1.194 | 0.128 | 1.013 | 0.892 |
| <i>GALNT2</i> | rs35498929 | T | C | 0.773 | 0.522 to 1.145 | 0.199 | 1.110 | 0.963 to 1.280 | 0.151 | 0.972 | 0.870 |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 0.741 | 0.496 to 1.108 | 0.145 | 0.848 | 0.730 to 0.985 | 0.031 | 0.834 | 0.012 |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.852 | 0.612 to 1.187 | 0.344 | 1.033 | 0.907 to 1.177 | 0.624 | 0.999 | 0.991 |
| Nephropathy | | | | DiaGene | | | Hoorn DCS | | | Meta-Analysis | |
| <i>GALNT2</i> | rs4846913 | A | C | 0.868 | 0.701 to 1.076 | 0.197 | 0.980 | 0.896 to 1.072 | 0.665 | 0.961 | 0.373 |
| <i>GALNT2</i> | rs35498929 | T | C | 1.061 | 0.783 to 1.437 | 0.704 | 0.967 | 0.844 to 1.108 | 0.625 | 0.982 | 0.768 |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 1.082 | 0.805 to 1.454 | 0.601 | 0.934 | 0.818 to 1.066 | 0.310 | 0.957 | 0.477 |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.968 | 0.725 to 1.293 | 0.827 | 0.981 | 0.869 to 1.108 | 0.760 | 0.979 | 0.714 |

| Neuropathy | | | | DiaGene | | | Hoorn DCS | | | Meta-Analysis | |
|-----------------------------|------------|----|----|---------|----------------|-----------------|-----------|----------------|-----------------|---------------|-----------------|
| Locus | rsID | EA | RA | HR | 95% CI | <i>p</i> -Value | HR | 95% CI | <i>p</i> -Value | HR | <i>p</i> -Value |
| <i>GALNT2</i> | rs4846913 | A | C | 1.034 | 0.822 to 1.300 | 0.778 | NA | NA | NA | NA | NA |
| <i>GALNT2</i> | rs35498929 | T | C | 1.285 | 0.917 to 1.801 | 0.145 | NA | NA | NA | NA | NA |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 0.990 | 0.694 to 1.411 | 0.956 | NA | NA | NA | NA | NA |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.860 | 0.618 to 1.197 | 0.370 | NA | NA | NA | NA | NA |
| Macrovascular Complications | | | | DiaGene | | | Hoorn DCS | | | Meta-Analysis | |
| <i>GALNT2</i> | rs4846913 | A | C | 0.938 | 0.665 to 1.323 | 0.716 | 0.999 | 0.872 to 1.143 | 0.983 | 0.991 | 0.883 |
| <i>GALNT2</i> | rs35498929 | T | C | 0.906 | 0.551 to 1.490 | 0.698 | 1.151 | 0.947 to 1.399 | 0.156 | 1.116 | 0.236 |
| <i>GALNT2:RP5-956O18.3</i> | rs3213497 | T | C | 1.387 | 0.865 to 2.226 | 0.175 | 0.870 | 0.707 to 1.071 | 0.189 | 1.045 | 0.848 |
| <i>IFT172/NRBP1</i> | rs67086575 | G | A | 0.687 | 0.400 to 1.179 | 0.173 | 1.002 | 0.836 to 1.202 | 0.979 | 0.907 | 0.558 |

Beta represents the change of incidence of the respective complication per increase of the effect allele. Bold for $p < 0.05$, bold and underlined for $p < 0.013$. EA, effect allele; RA, reference allele; NA, not available.

| Neuropathy | Sens. Lipid Meds | | | | Sens. Insulin use | | | | Hoorn DCS | | | |
|------------|------------------|------------|----------|----|-------------------|-----------------|-------|---------|-----------|-----------------|-------|---------|
| | uniqlID | rsID | Dla Gene | | HR | 95% C.I. for HR | | p-value | HR | 95% C.I. for HR | | p-value |
| | | | EA | RA | | lower | upper | | | lower | upper | |
| | 1:230294715:A:C | r54846913 | A | C | 1.005 | 0.794 | 1.272 | 0.968 | NA | NA | NA | 0.702 |
| | 1:230286016:C:T | r535498929 | T | C | 1.273 | 0.906 | 1.787 | 0.164 | NA | NA | NA | 0.185 |
| | 1:230416320:C:T | r53213497 | T | C | 0.977 | 0.684 | 1.396 | 0.897 | NA | NA | NA | 0.868 |
| | 2:27686480:A:G | r567086575 | G | A | 0.854 | 0.613 | 1.189 | 0.349 | NA | NA | NA | 0.336 |

| Cardiovascular disease | Sens. Lipid Meds | | | | Sens. Insulin use | | | | Hoorn DCS | | | |
|------------------------|------------------|------------|----------|----|-------------------|-----------------|-------|---------|-----------|-----------------|-------|---------|
| | uniqlID | rsID | Dla Gene | | HR | 95% C.I. for HR | | p-value | HR | 95% C.I. for HR | | p-value |
| | | | EA | RA | | lower | upper | | | lower | upper | |
| | 1:230294715:A:C | r54846913 | A | C | 0.942 | 0.668 | 1.329 | 0.735 | 0.998 | 0.872 | 1.143 | 0.982 |
| | 1:230286016:C:T | r535498929 | T | C | 0.911 | 0.554 | 1.498 | 0.712 | 1.151 | 0.947 | 1.398 | 0.157 |
| | 1:230416320:C:T | r53213497 | T | C | 1.382 | 0.861 | 2.219 | 0.180 | 0.870 | 0.707 | 1.071 | 0.190 |
| | 2:27686480:A:G | r567086575 | G | A | 0.691 | 0.402 | 1.187 | 0.180 | 1.003 | 0.836 | 1.204 | 0.972 |

Bold for p<0.05, bold and underlined for p<0.05/4=0.013, EA, effect allele; RA, reference allele

DISCUSSION

In the present study, we found that apo-CIII glycosylation (specifically, sialylation) and the linked *GALNT2*-gene variant were associated with the prevalence and incidence of diabetic retinopathy. This suggests that glycosylation determines apo-CIII function and decreased glycosylation of apo-C-III contributes to the development of retinopathy. Further, apo-CIII glycosylation was associated with prevalent diabetic neuropathy and macrovascular complications.

Type 2 diabetes is characterised by insulin resistance and an inadequate compensatory insulin secretory response, resulting in chronic hyperglycaemia²¹⁹. Glucose and insulin oppositely modulate the expression of apo-CIII^{125, 224}. This could explain the high apo-CIII secretion rate in the presence of type 2 diabetes²²⁵. So far, no other studies have investigated the relationships between apo-CIII glycosylation, its genetic background, and complications of type 2 diabetes. Here, the current study findings are discussed for each complication and potential underlying mechanisms will be hypothesised considering the limited pathophysiological information that is available in the current literature.

The most pronounced finding of this study was the connection of *GALNT2*, apo-CIII glycosylation and diabetic retinopathy (**Figure 2**). Previously, we identified a genetic variant rs4846913-A, located in the *GALNT2* gene, that was negatively associated with non-glycosylated apo-CIII (apo-CIII_{0a})²²¹. The A-allele of this rs4846913 variant is known to increase the expression of the *GALNT2*-gene¹⁹⁴, which encodes a GalNAc-transferase that initiates mucin-type *O*-glycosylation of peptides, such as apo-CIII¹⁷⁵. The rs4846913-A variant comes with higher glycosylation levels of apo-CIII. Although only within the DiaGene cohort, this variant was negatively associated with retinopathy. In line, increased apo-CIII_{0a} was associated with the prevalence of retinopathy. Replication in a larger cohort is needed to confirm whether increased activity of *GALNT2* reduces the risk of retinopathy through glycosylation of apo-CIII. This might be an interesting target for prevention or treatment of diabetic retinopathy.

Diabetes complications develop through an interplay of risk factors, including glucose and lipid metabolism, in which apo-CIII plays a role. Previously, we have analysed apo-CIII glycosylation profiles in over 700 people without diabetes¹⁷⁹. Our findings supported other studies demonstrating a positive association between the apo-CIII₁/apo-CIII₂ ratio and triglyceride levels, implying the involvement of apo-CIII sialylation in an impaired triglyceride clearance⁵⁷⁻⁵⁹. In line, the removal of sialic acids from apo-CIII by neuraminidase treatment decreases its potential to inhibit LPL¹³⁵. A recent study by Kegulian et al. has shown that the two sialylated glycoforms (apo-CIII₁ and apo-CIII₂) are cleared differently by hepatic receptors, specifically heparan sulphate proteoglycans (HSPGs) such as syndecan-1 (SDC1), LDL-receptor (LDLR), and LDL receptor-related protein 1 (LRP1)⁵⁹. In people with type 2 diabetes, the LDL particles carry more apo-CIII₂ and less apo-CIII₁ than in those without diabetes¹³⁶. Molecular mechanisms behind the association of apo-CIII₁ and apo-CIII₂ with triglyceride levels and vascular disease have not been fully elucidated. Mauger et al. found a positive association of small dense LDL with the production rate of apo-CIII₂¹⁶¹. Hiukka et al. reported an essential role of sialylation for the proinflammatory effect of LDL-bound apo-CIII on human aortic endothelial cells (HAECs). They found an increased immune response of HAECs after incubation with LDL containing apo-CIII₂, while the immune response after incubation with LDL containing apo-CIII₀ or apo-CIII₁ did not differ from apo-CIII-free LDL¹³⁶. It is difficult to explain how the effects on large vessels translate to small vessel disease. Nevertheless, inflammation and dyslipidaemia are known risk factors for micro- and macrovascular complications of diabetes²²⁶. Moreover, higher serum sialic acid levels have been associated with inflammation²²⁷ and coronary artery disease²²⁸. An increased immune response-related change in sialylation might explain our positive association of apo-CIII₂ with retinopathy. Taken together, the association of apo-CIII sialylation with retinopathy might reflect causality. Nevertheless, the current literature does not provide a complete explanation of the pathophysiological pathway of this association.

A negative association of rs3213497-T and apo-CIII₁ with nephropathy was found. Notably, rs3213497-T was associated with decreased apo-CIII_{0a} levels at a suggestive significance level ($p = 1.30 \times 10^{-7}$), but not with apo-CIII₁ in our previous GWAS²²¹. Here, only apo-CIII₁, and not apo-CIII_{0a}, presented a suggestive significance level negative association with nephropathy. The negative association of apo-CIII₁ with nephropathy was in line with an increase in the apo-CIII₂/Apo-CIII₁ ratio in VLDL reported in a small sample of chronic kidney disease²²⁹. The associations of apo-CIII glycosylation with nephropathy did not reach significance after Bonferroni correction. Nevertheless, the directions of effect were similar to the associations of apo-CIII glycosylation with retinopathy, which is also a micro-vascular complication of diabetes, with overlapping risk factors²²⁶.

Studied only in a hospital-treated subgroup of the DiaGene study, monosialylated apo-CIII (apo-CIII₁) levels were positively associated with neuropathy. This trend remained in all subsequent models, independent of the duration of diabetes, glucose metabolism, the use of statins or fibrates, or insulin. Neuropathy showed an opposite direction of effect compared to retinopathy and nephropathy. Possibly, the association with apo-CIII₁ was driven by differences in disease severity or other comorbidities of this hospital-treated subgroup.

Non-glycosylated apo-CIII (apo-CIII_{0a}) was negatively associated with the prevalence of macrovascular complications. This association lost significance after the addition of lipid-reducing agents to the statistical model. The use of lipid-reducing agents was associated with lower relative levels of apo-CIII_{0a} (**Supplementary Table S4**). Possibly, the use of lipid-lowering medication alters the proportion of apo-CIII_{0a} and drives the association of apo-CIII_{0a} with macrovascular disease.

As for the strengths of this study, this is the first report investigating associations of apo-CIII glycosylation with micro- and macrovascular complications in type 2 diabetes. We used a high-resolution MS method to assess the apo-CIII glycosylation patterns in blood plasma within a large cohort of type 2 diabetes patients from all lines of care and

replicated our genetic findings in a second cohort. The DiaGene cohort served as a high-risk population for discovery analyses, while genetic associations could even be replicated in the relatively lower-risk population of Hoorn DCS. Many clinical features of these patients were available for the analysis, allowing us to correct for possible confounders. Furthermore, we were able to investigate findings on glycosylation in the light of genetic background derived from GWASs, allowing us to assess a potential direction of effect and causality for some of the associations.

Some limitations of our study remain. The most important limitation is the amount of prospective data: the sample size for the prospective analysis was small and we had a follow-up with a median of 7.8 and 9.0 years in the DiaGene and Hoorn DCS study respectively. Due to the relatively small effect sizes, strong conclusions on effect sizes cannot be drawn. Also, the data on neuropathy were incomplete, resulting in low power for the analyses of neuropathy. The apo-CIII glycosylation profiling was performed with blood samples collected at baseline, so we were not able to assess glycosylation changes over time. Furthermore, absolute apo-CIII plasma levels were not measured; therefore, adjustment for these levels was not possible. Nevertheless, expression rates of apo-CIII₁ and apo-CIII₂ in humans are comparable¹⁶¹, and the distribution of glycoforms in plasma is stable in variable apo-CIII concentrations in young, healthy men²³⁰. In coronary artery disease patients, apo-CIII₂ remains stable across apo-CIII plasma concentrations, while apo-CIII_{0c} decreased and apo-CIII₁ increased with increasing total apo-CIII¹⁵⁰. Adjustment for total plasma apo-CIII concentrations did not affect the association of apo-CIII₂ with plasma triglycerides, according to Koska et al.⁵⁷. Insulin levels were not available which would have been interesting in light of the effects of apo-CIII on beta cell function. Finally, the cohort was mainly of European descent; therefore, we cannot generalise our findings to other ethnic groups.

In conclusion, our findings indicate a relationship between apo-CIII glycosylation and retinopathy, neuropathy, and macrovascular complications. In addition, a genetic

variant in the *GALNT2*-gene, previously linked to increased glycosylation of apo-CIII, was found to be negatively associated with retinopathy. Future research to further investigate the possible causal pathway of retinopathy development through aberrant apo-CIII glycosylation is warranted. Together, the current study findings suggest that apo-CIII glycosylation should be considered as a potential diagnostic and therapeutic target for diabetes complications.

Acknowledgements

This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 722095 "GlySign".

The authors would like to thank the participants and staff of Diabetes Care System West-Friesland and the DiaGene Study for their cooperation and support.